Panobinostat Lactate Patent Expiration
Panobinostat Lactate is Used for treating multiple myeloma in combination with bortezomib and dexamethasone. It was first introduced by Secura Bio Inc
Panobinostat Lactate Patents
Given below is the list of patents protecting Panobinostat Lactate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Farydak | US8883842 | Use of HDAC inhibitors for the treatment of myeloma | Jun 13, 2028 | Secura |
| Farydak | US7989494 | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | Jan 17, 2028 | Secura |
| Farydak | US6833384 | Deacetylase inhibitors |
Sep 30, 2021
(Expired) | Secura |
| Farydak | US6552065 | Deacetylase inhibitors |
Aug 31, 2021
(Expired) | Secura |
| Farydak | US7067551 | Deacetylase inhibitors |
Aug 31, 2021
(Expired) | Secura |
Panobinostat Lactate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List